Latest announcements from Veos Pharmaceuticals across corporate developments, product launches, awards, and strategic partnerships.
Veos Pharmaceuticals has secured funding under the Innowwide Call 4 programme of the Eureka Network for BIOPRO-JP (ref. 2025-25398), ...
Anuncio acuerdo de fusión por absorción. En cumplimiento del artículo 10 del RDL 5/2023, se anuncia la fusión por absorción aprobada por unanimidad el 11 de marzo de 2026.
Spanish specialty healthcare company strengthens its footprint in Canada through the acquisition of leading Amazon-native consumer health and pet-care brands — including Copper Heal™, Petting is Caring™, and F1TNERGY™.
Veos Pharmaceuticals S.L., a Spain-based biotechnology company pioneering natural innovations for health and sustainability, has won Third Prize at the 9th China (Shenzhen) IEIC — Barcelona Division — recognizing ThymoTropin™ and advancing to the Shenzhen Industrial Phase.
Veos Pharmaceuticals is proud to announce its selection to present at the Europe–Japan SALON Part 4, organized by SAKURA DEEPTECH Shibuya and the EU–Japan Centre for Industrial Cooperation, in Tokyo on September 3, 2025.
We are honored to announce that OliQuell™, our natural solution for environmental remediation, has been selected for the Smart Energy Week Autumn 2025 Business Mission in Japan, organized by the EU Business Hub.
Veos Pharmaceuticals S.L. is pleased to announce that it has been awarded a public subsidy in the amount of €8,000 by the Community of Madrid under the Programa para el fomento de la contratación, supporting stable, long-term employment in the region.
Clinically Proven Myostatin-Targeting Formula to Enhance Muscle Growth, Repair, and Endurance — powered by clinically validated thymol and carvacrol, addressing muscle loss in aging, chronic disease, and GLP-1 treatment populations.